The vaccine doesn't have to be stored at ultra-cold temperatures, giving public health officials hope they may soon have access to a vaccine that is cheaper and easier to distribute than some of its rivals.
It has secured 100 million doses of the vaccine developed by AstraZeneca and Oxford University and has targeted a rollout to begin before Christmas.
Two other drugmakers, Pfizer and Moderna, last week reported preliminary results from late-stage trials showing their Covid-19 vaccines were nearly 95 per cent effective.
In the low-dose group, AstraZeneca said the vaccine appeared to be 90 percent effective, while the two-dose group appeared to be 62 percent effective, however the way in which the vaccines were Results were reported by companies led to prompt questions from experts.More news: Florida quickly approaching 1 million COVID-19 cases
In the United States, the first people to receive the Pfizer vaccine would likely include doctors, nurses and front-line emergency medical personnel, as well as those at the highest risk of severe illness and death from the virus, Slaoui said.
He told The Andrew Marr Show on the BBC: "I would personally be happy to have any vaccine that's been through the regulatory scrutiny that these trials are now undergoing".
Britain on Friday asked its medicine regulator to assess if the vaccine candidate met rigorous safety standards with a view for temporary supply, a step towards beginning a roll-out of the vaccine before the end of the year. The European Medicines Agency said on Thursday it would "assess data on the efficacy and safety of the vaccine in the coming weeks".
Clearance from the US Food and Drug Administration (FDA) may take longer, though, because the agency is unlikely to approve the vaccine based on studies carried out elsewhere, especially given the questions over the results, Soriot said.
AstraZeneca research chief Mene Pangalos told Reuters on Monday that researchers had stumbled upon the half-dose regime by accident, saying a sub-group of the trial was given a smaller initial dose by mistake.More news: Seventh Pakistan team member tests positive for Covid-19 in New Zealand
The U.K. government has agreed to buy more than 350 million doses of vaccines from seven different producers, should they prove effective, as it prepares to vaccinate as numerous country's 67 million people as possible.
Australian Prime Minister Scott Morrison, talking to media, expressed confidence about the vaccine, which is being manufactured by the country's biomedical giant CSL Ltd.
"Even the lowest efficacy results are at 60-70%, making it a viable vaccine against the virus", the institute said in a statement, adding that the trials were running smoothly.
The Serum Institute of India is conducting trials of the vaccine there.More news: Tyson fights to draw with Jones Jr. in exhibition